Mertsola J, Viljanen M K, Ruuskanen O
Ann Clin Res. 1982 Dec;14(5-6):253-9.
The pertussis vaccination programme was started in Finland in 1952. Since then the incidence of the disease has decreased. No major epidemics have occurred during the last two decades. The majority of the patients with pertussis are children of school age. Their disease is characterized by prolonged cough without whooping and it is difficult to diagnose. The patients with atypical pertussis are, however, the major reservoir for transmission of the disease to young infants, in whom it can be serious. Recently developed ELISA for measuring antipertussis IgM and IgA antibodies is a valuable aid in the diagnosis of these cases. Pertussis vaccination has been a subject of considerable controversy in recent years. The vaccine used in Finland has proved to be safe and effective. This observation emphasizes the need for careful comparison of the vaccines used in different countries.
芬兰于1952年开始实施百日咳疫苗接种计划。自那时起，该疾病的发病率有所下降。在过去二十年中未发生重大疫情。大多数百日咳患者是学龄儿童。他们的疾病特征是持续咳嗽而无哮吼声，且难以诊断。然而，非典型百日咳患者是该疾病传播给幼儿的主要传染源，而幼儿感染后病情可能很严重。最近开发的用于检测抗百日咳IgM和IgA抗体的酶联免疫吸附测定法（ELISA）在诊断这些病例时是一项有价值的辅助手段。近年来，百日咳疫苗接种一直是一个备受争议的话题。芬兰使用的疫苗已被证明是安全有效的。这一观察结果强调了仔细比较不同国家使用的疫苗的必要性。
